For people with ROS1-positive lung cancer or other solid tumours, treatment options often remain limited, particularly when earlier therapies stop working or when the disease has spread to the brain. That is why it matters that new research is taking place which addresses these needs.
An international team of doctors and researchers is currently running a phase 2 study of zidesamtinib (NVL-520), an experimental medicine developed specifically for tumours with a ROS1 rearrangement. The agent is designed to deal better with treatment resistance, brain metastases and certain side effects that occur with other therapies.
Who is the study for?
The study is open to:
-
People aged 12 and over with advanced or metastatic ROS1-positive cancer.
-
People with ROS1-positive non-small cell lung cancer who have not previously received a ROS1-targeted TKI treatment.
-
Adults and young people aged 12 and over with another ROS1-positive solid tumour.
In addition, the disease must be measurable on scans, and general organ and blood function must be sufficiently good. A doctor familiar with your file can quickly check whether you meet the conditions.
Who cannot take part?
Among others, people with another known genetic driver of their tumour, people who have recently undergone major surgery, or people currently taking part in another therapeutic study cannot participate. Your doctor can easily verify this.
Why might this research be of interest?
For many patients, treatment options narrow as the disease progresses. This study is investigating a new, targeted therapy that may address other forms of resistance and that has also been developed with brain metastases in mind. For some patients this may be an opportunity to access a treatment that is not yet widely available.
More information or taking part?
Anyone who wants to know whether participation is possible can discuss this with their treating physician. Doctors can consult all the technical criteria and details on the official study site (ClinicalTrials.gov, study code NCT05118789).
Further questions can also be sent by email to: clinicaltrials@nuvalent.com